InflaRx N.V. (IFRX) analyst actions
Rating and price-target actions on IFRX in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the IFRX overview →
1 measured IFRX analyst action event.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| InflaRx Announces Initiation of its Commitment Program for GOHIBIC®(vilobelimab) to Help Broaden Access for Eligible Patients | Press release | +0.00% | -10.71% |
Keep exploring
More IFRX: earnings → · SEC filings → · IFRX overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Alimera Sciences, Inc. (ALIM) | 142 | 0.00% | 42% |
| G1 Therapeutics, Inc. (GTHX) | 142 | +0.21% | 66% |
| Oncocyte Corporation (OCX) | 141 | 0.00% | 47% |
| ImmunoGen, Inc. (IMGN) | 140 | +0.07% | 56% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.